Proteus Syndrome
5 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| MK-7075 (Miransertib) in Proteus Syndrome (NCT04316546) | National Human Genome Research Institute (NHGRI) | 2022-05-20 |
| Dose Finding Trial of MK-7075 in Children and Adults With Proteus Syndrome (NCT02594215) | National Human Genome Research Institute (NHGRI) | 2015-11-16 |
| Informed Consent for Whole Genome Sequencing: Ideals and Norms Referenced by Early Participants (NCT01369953) | National Human Genome Research Institute (NHGRI) | 2011-05-29 |
| Study of Proteus Syndrome and Related Congenital Disorders (NCT00001403) | National Human Genome Research Institute (NHGRI) | 1994-04-27 |
| Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies (NCT03317366) | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) |
Track Proteus Syndrome automatically
Every clearance here is in the API, with alerts when new ones post.